Further observations on the immune response to recombinant hepatitis B vaccine after administration to Aboriginal and Torres Strait Island children
| Autor: | J W Sheridan, J L Faoagali, Jeffrey N Hanna, P J Buda |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Hepatitis B virus HBsAg Native Hawaiian or Other Pacific Islander Hepatitis B vaccine Immunization Secondary Booster dose medicine.disease_cause Cohort Studies Hepatitis B Antigens Seroepidemiologic Studies Immunity medicine Humans Hepatitis B Vaccines Vaccines Synthetic business.industry Vaccination Australia Infant Hepatitis B medicine.disease Virology Cross-Sectional Studies Child Preschool Carrier State Pediatrics Perinatology and Child Health Immunology Female Viral disease business |
| Zdroj: | Journal of Paediatrics and Child Health. 33:67-70 |
| ISSN: | 1440-1754 1034-4810 |
| DOI: | 10.1111/j.1440-1754.1997.tb00994.x |
| Popis: | Objective: To determine the prevalence of markers of hepatitis B virus (HBV) immunity and infection at 5 years of age in Aboriginal and Torres Strait Island children who were fully vaccinated in infancy, and to examine the response to a booster dose of hepatitis B vaccine in those children who had no detectable immunity despite vaccination. Methodology: A cross-sectional study of serological markers to HBV in a sample of 239 Aboriginal and Torres Strait Island children, with a mean age of 5.7 years, who were fully vaccinated in infancy. The antibody response to a booster dose of hepatitis B vaccine was determined in those children in the sample who had no markers of either immunity to HBV or infection with HBV. Results: Of the 239 children, 6% (95% Cl 4–10%) had been infected and, of these, four were HBV surface antigen (HBsAg) positive. Of the remaining 224 children, only 41% (95% Cl 35–48%) had evidence of immunity (i.e. an antibody to HBV surface antigen (anti-HBs) level of ≥10 miu/mL) to HBV. Of the children with no detectable immunity (i.e. anti-HBs < 10 miu/mL), 113 were followed up after receiving a booster dose of hepatitis B vaccine. Of these, 84% (95% Cl 76–90%) had an anamnestic response (i.e. anti-HBs |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text